Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: December 18, 2012
Last updated: June 16, 2016
Last verified: June 2016
In patients with advanced levodopa-responsive Parkinson's Disease and severe motor fluctuations despite optimized treatment with conventional oral Parkinson's Disease medications, treatment with Duodopa represents an alternative treatment option to improve motor, non-motor performance and overall quality of life. These benefits have been obtained in short and mid-term trials (mainly up to 2 years). Data on long-term effectiveness (5 years of treatment or more) and safety are not available. Also data concerning the benefit of Duodopa on cognitive function, axial symptoms and disability have to be confirmed. Recent data on deep brain stimulation (DBS), the alternative option treatment in advanced Parkinson's Disease patients, showed that after 5 years from the implant, a worsening of axial symptoms (gait and balance) and after 1 to 3 years of speech could occur. Moreover, it has never been assessed if the benefit on motor and non-motor symptoms in patients treated with DUODOPA could be influenced by age and duration of the disease, as already shown for DBS implanted patients. This study should clarify the missing information on long-term benefit of Duodopa (up to 7 years) especially focusing on motor fluctuations and disability.

Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Change in Unified Parkinson Disease Rating Scale (UPDRS) IV - item 39 (proportion of waking day spent in "OFF") [ Time Frame: From Day 0 to month 24 ]

Secondary Outcome Measures:
  • Change in Unified Parkinson's disease rating scale on complications of therapy (UPDRS IV) [ Time Frame: From Day 0 to month 24 ]
  • Change in Unified Parkinson's disease rating scale on Mentation, Behavior and Mood (UPDRS I), on Activities of Daily Living (UPDRS II) for both in OFF and in ON phase. [ Time Frame: From Day 0 to month 24 ]
  • Change in Parkinson Disease Quality of Life Questionnaire in 39 items (PDQ 39) [ Time Frame: From Day 0 to month 24 ]
  • Change in Parkinson Disease Sleep Scale version 2 (PDSS-2) [ Time Frame: From Day 0 to month 24 ]
  • Change in Gait and Fall Questionnaire [ Time Frame: From Day 0 to month 24 ]
  • Change in Questionnaire for Impulsive -Compulsive Disorders in Parkinsons' Disease (QUIP-RS) [ Time Frame: From Day 0 to month 24 ]
  • Change in Economical and social impact of the familiar healthcare [ Time Frame: From Day 0 to month 24 ]
  • Change in Relative Stress Scale questionnaire (RSS) [ Time Frame: From Day 0 to month 24 ]
  • Change in Concomitant diseases and therapies [ Time Frame: From Day 0 to month 24 ]
  • Change in Global efficacy on motor symptoms rated by neurologists vs baseline on a three-point scale: improvement, no change, worsening [ Time Frame: From Day 0 to month 24 ]
  • Change in Self-assessment patients scale regarding their judgement on Duodopa therapy, rated from 0 to 10 and assessed as follows: 0-2: worse, 3-5 unsatisfactory, 6-8 satisfactory, 9-10 very good [ Time Frame: From Day 0 to month 24 ]
  • Change in Duodopa daily infusion dosage [ Time Frame: From Day 0 to month 24 ]

Enrollment: 148
Study Start Date: December 2012
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Parkinson's Disease patient
Patients with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who are prescribed and treated in accordance with local DUODOPA® product label under the conditions of a routine clinical setting.

Detailed Description:
Post Marketing Observational Study to document the long-term clinical effectiveness of DUODOPA in Parkinson Disease patients under the conditions of a routine clinical setting.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients already on treatment with DUODOPA® according local DUODOPA® product label (treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper/dyskinesia when available combinations of PD medicinal products have not given satisfactory results) and according to specific reimbursement criteria will be offered the opportunity to enroll in this study.

Inclusion Criteria:

  • Patients already on treatment with DUODOPA ® (having already concluded the naso-intestinal phase) according to the local DUODOPA® product label and to clinical routine care for advanced PD patients
  • Patients with available data on Duodopa treatment, on previous PD conventional treatments and with at least one of the scales/questionnaires under study already collected on the patient clinical chart
  • Patient or legal representative has given written informed consent
  • Non-professional caregiver (relative or familiar who give daily assistance to the patient) has given his/her written consent

Exclusion Criteria:

• History or presence of any condition that might interfere with the long-term continuation of the duodenal infusion of DUODOPA

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01754129

Site Reference ID/Investigator# 83929
Acquaviva delle Fonti, Italy, 70021
Site Reference ID/Investigator# 83717
Catania, Italy, 95121
Site Reference ID/Investigator# 83721
Ferrara, Italy, 44100
Site Reference ID/Investigator# 83720
Mestre, Italy, 30174
Site Reference ID/Investigator# 83713
Milan, Italy, 20139
Site Reference ID/Investigator# 83924
Monserrato, Cagliari, Italy, 09042
Site Reference ID/Investigator# 83719
Pavia, Italy, 27100
Site Reference ID/Investigator# 83715
Ponderano, Biella, Italy, 13875
Site Reference ID/Investigator# 83718
Pozzilli, Italy, 86077
Site Reference ID/Investigator# 83926
Rome, Italy, 00165
Site Reference ID/Investigator# 83927
Rome, Italy, 00165
Site Reference ID/Investigator# 83714
Salerno, Italy, 84131
Site Reference ID/Investigator# 83716
Turin, Italy, 10126
Site Reference ID/Investigator# 83925
Udine, Italy, 33100
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Koray Onuk AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01754129     History of Changes
Other Study ID Numbers: P13-895 
Study First Received: December 18, 2012
Last Updated: June 16, 2016

Keywords provided by AbbVie:
Quality of Life
Parkinson's Disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors processed this record on January 19, 2017